Drug Profile

Amelparib - Jeil Pharmaceutical

Alternative Names: JI-6289; JPI-289; OJP-3101

Latest Information Update: 13 Oct 2021

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Jeil Pharmaceutical
Developer Jeil Pharmaceutical; Oncocross
Class Anti-ischaemics; Ethers; Morpholines; Naphthyridines; Small molecules
Mechanism of Action Poly(ADP-ribose) polymerase inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

Highest Development Phases

Phase II Stroke
Preclinical Unspecified

Most Recent Events

07 Oct 2021 Preclinical trials in Unspecified in South Korea (unspecified route) before October 2021 (Oncocross' pipeline, October 2021)
25 Sep 2020 Amelparib is still in phase II trials for Stroke in South Korea (NCT03062397)
01 Aug 2019 Chemical structure information added

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com